CA2732440C - Cystamine analogues for the treatment of parkinson`s disease - Google Patents

Cystamine analogues for the treatment of parkinson`s disease Download PDF

Info

Publication number
CA2732440C
CA2732440C CA2732440A CA2732440A CA2732440C CA 2732440 C CA2732440 C CA 2732440C CA 2732440 A CA2732440 A CA 2732440A CA 2732440 A CA2732440 A CA 2732440A CA 2732440 C CA2732440 C CA 2732440C
Authority
CA
Canada
Prior art keywords
cystamine
pharmaceutically acceptable
cysteine
acceptable salt
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2732440A
Other languages
English (en)
French (fr)
Other versions
CA2732440A1 (en
Inventor
Francesca Cicchetti
Claude Rouillard
Frederic Calon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Laval
Original Assignee
Université Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2732440A priority Critical patent/CA2732440C/en
Application filed by Université Laval filed Critical Université Laval
Priority to AU2012220314A priority patent/AU2012220314B2/en
Priority to MX2013009608A priority patent/MX350195B/es
Priority to PCT/CA2012/050106 priority patent/WO2012113079A1/en
Priority to CN2012800099995A priority patent/CN103442704A/zh
Priority to KR1020137024680A priority patent/KR20140115239A/ko
Priority to US14/000,234 priority patent/US20140073694A1/en
Priority to JP2013554768A priority patent/JP6000985B2/ja
Priority to RU2013137645A priority patent/RU2630583C2/ru
Priority to BR112013021616-6A priority patent/BR112013021616A2/pt
Priority to EP12750124.5A priority patent/EP2678009B1/en
Publication of CA2732440A1 publication Critical patent/CA2732440A1/en
Application granted granted Critical
Publication of CA2732440C publication Critical patent/CA2732440C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2732440A 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease Expired - Fee Related CA2732440C (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2732440A CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease
RU2013137645A RU2630583C2 (ru) 2011-02-23 2012-02-23 Аналоги цистамина, применяемые для лечения болезни паркинсона
PCT/CA2012/050106 WO2012113079A1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease
CN2012800099995A CN103442704A (zh) 2011-02-23 2012-02-23 用于治疗帕金森病的胱胺类似物
KR1020137024680A KR20140115239A (ko) 2011-02-23 2012-02-23 파킨슨병 치료용 시스타민 유사체
US14/000,234 US20140073694A1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease
AU2012220314A AU2012220314B2 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of Parkinson's disease
MX2013009608A MX350195B (es) 2011-02-23 2012-02-23 Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
BR112013021616-6A BR112013021616A2 (pt) 2011-02-23 2012-02-23 análogos de cistamina para o tratamento de doença de parkinson
EP12750124.5A EP2678009B1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease
JP2013554768A JP6000985B2 (ja) 2011-02-23 2012-02-23 パーキンソン病を治療するためのシスタミン類似体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2732440A CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease

Publications (2)

Publication Number Publication Date
CA2732440A1 CA2732440A1 (en) 2012-08-23
CA2732440C true CA2732440C (en) 2017-10-31

Family

ID=46717621

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2732440A Expired - Fee Related CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease

Country Status (11)

Country Link
US (1) US20140073694A1 (enExample)
EP (1) EP2678009B1 (enExample)
JP (1) JP6000985B2 (enExample)
KR (1) KR20140115239A (enExample)
CN (1) CN103442704A (enExample)
AU (1) AU2012220314B2 (enExample)
BR (1) BR112013021616A2 (enExample)
CA (1) CA2732440C (enExample)
MX (1) MX350195B (enExample)
RU (1) RU2630583C2 (enExample)
WO (1) WO2012113079A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
WO2017166139A1 (zh) 2016-03-30 2017-10-05 广东欧珀移动通信有限公司 中继传输的方法和装置
WO2020198529A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Ofcalifornia Substituted amino-thiol and amino-disulfide compounds, and uses thereof
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN119909064B (zh) * 2025-04-07 2025-08-15 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211624A1 (en) * 2003-02-02 2006-09-21 Goverment of the US, as Represented by Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies
RU2255775C1 (ru) * 2003-12-25 2005-07-10 Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук Способ лечения болезни паркинсона
WO2007089670A2 (en) * 2006-01-27 2007-08-09 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
WO2008143876A2 (en) * 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON

Also Published As

Publication number Publication date
BR112013021616A2 (pt) 2020-09-29
US20140073694A1 (en) 2014-03-13
MX350195B (es) 2017-08-30
AU2012220314A1 (en) 2013-08-22
EP2678009A1 (en) 2014-01-01
JP2014508758A (ja) 2014-04-10
RU2013137645A (ru) 2015-02-20
KR20140115239A (ko) 2014-09-30
MX2013009608A (es) 2013-09-16
WO2012113079A1 (en) 2012-08-30
EP2678009A4 (en) 2014-08-06
AU2012220314B2 (en) 2017-04-06
CN103442704A (zh) 2013-12-11
CA2732440A1 (en) 2012-08-23
EP2678009B1 (en) 2017-11-01
RU2630583C2 (ru) 2017-09-11
JP6000985B2 (ja) 2016-10-05

Similar Documents

Publication Publication Date Title
EP2678009B1 (en) Cystamine analogues for the treatment of parkinson&#39;s disease
Ma et al. BCAA–BCKA axis regulates WAT browning through acetylation of PRDM16
Rausch et al. From the tyrosine hydroxylase hypothesis of Parkinson’s disease to modern strategies: a short historical overview
Wang et al. Regulation of the kynurenine/serotonin pathway by berberine and the underlying effect in the hippocampus of the chronic unpredictable mild stress mice
JP7385924B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物
KR20230023642A (ko) 간 장애의 조합 치료
US10159678B2 (en) Methods to decrease susceptibility to asthmatic bronchoconstriction
CN103189056A (zh) L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗
Trinity et al. Cardiovasomobility: an integrative understanding of how disuse impacts cardiovascular and skeletal muscle health
Wang et al. Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models
JP5901770B2 (ja) Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
C Brett et al. Current therapeutic advances in patients and experimental models of Huntington's disease
US20230128194A1 (en) Methods and compositions to alter hepatic gaba release to treat obesity-related conditions
Dhir et al. Nitric oxide (NO) system in major depression: studies on NO synthase inhibitors as antidepressant agents
Mullins BT2 as a novel therapeutic compound for Alzheimer’s disease
Albano Regulation of the cystine/glutamate antiporter and its contribution to neuronal death
WO2025239337A1 (ja) カテコールアミン作動性ニューロンからのカテコールアミンの放出抑制用医薬組成物
AU2007203426B8 (en) Methods for treating neuropsychiatric disorders with NMDA receptor antagonists
Jideonwo Novel roles of sterol regulatory element-binding protein-1 in liver
US20180235919A1 (en) System and Method For Treating Atheroma Formation
Ng Isoprenoids in Parkinson's disease
Jurkovic Hormonal Regulation of CYP2B6 and CYP2D6 Expression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160113

MKLA Lapsed

Effective date: 20200224